Search Results (247)

Background: Surgical procedures and alterations of the gastrointestinal (GI) tract increase the risk of small intestinal bacterial overgrowth (SIBO), which is associated with GI symptoms and complications that compromise postoperative recovery. However, the prevalence and clinical impact of SIBO after various upper GI surgical procedures remain poorly understood. Objective: This study aimed to evaluate the prevalence of SIBO after different types of upper GI surgery and to investigate the associated clinical factors. Methods: We conducted an observational study involving 157 patients with a history of upper GI surgery: Roux-en-Y gastric bypass (RYGB), laparoscopic single-anastomosis gastric bypass (OAGB), subtotal (STG) or total gastrectomy (TG), subtotal (SP)or total pancreatectomy (TP), cephalic duodenopancreatectomy (WR), and small bowel resection for Crohn’s disease. A glucose–hydrogen breath test was performed, and demographic, clinical, and treatment-related data were collected. Statistical analyses included t-tests, non-parametric tests, ANOVA, and correlation analyses using R software. Results: At a median follow-up of 25.7 ± 18.1 months, 31% (48/157) of patients tested positive for SIBO. The highest prevalence was observed after RYGB and OAGB (43%), followed by TG (30%), STG (29%), TP/WR (28%), and Crohn’s disease bowel resection (19%). No cases of SIBO were observed after SP. SIBO positivity was significantly associated with bloating and flatulence (p = 0.002), lactose intolerance (p = 0.047), systemic sclerosis (p = 0.042), T2D (p = 0.002), and exposure to adjuvant chemotherapy (p = 0.001) and radiotherapy (p = 0.027). In addition, the risk of SIBO increased proportionally with the duration of GI resection or exclusion (p = 0.013). Conclusions: In our study, the prevalence of SIBO after upper GI surgery was 31%, with the highest incidence (43%) observed in metabolic surgery patients. Importantly, adjuvant radio/chemotherapy was associated with an increased risk of SIBO, and extensive small bowel resection or exclusion was strongly associated with an increased risk of SIBO. Furthermore, the limitations of current diagnostic methods, which lack sufficient sensitivity and specificity, highlight the importance of early screening and standardization of diagnostic techniques to improve patient management and outcomes. Full article

Background and Clinical Significance: Roux-en-Y gastric bypass (RYGB) significantly alters glucose metabolism, yet managing glucose variability in patients undergoing bariatric surgery remains challenging. Continuous Glucose Monitoring (CGM) offers real-time insights into glucose fluctuations and may support long-term metabolic management in this population. This case highlights the utility of CGM in identifying postprandial glycemic variability and guiding dietary adjustments. Case Presentation: A 45-year-old female, 14 years post-RYGB, presented with symptoms including postprandial fatigue, nocturnal cravings, and unexplained weight gain, despite adherence to nutritional guidelines. Her BMI had decreased from 52 kg/m² (pre-surgery) to 29 kg/m². She was provided with a CGM device (FreeStyle Libre 3) by the clinical team and instructed to monitor glucose without modifying her routine initially. Data revealed significant glycemic variability, with peaks up to 220 mg/dL and hypoglycemic dips to 45 mg/dL. Based on this, she adjusted her diet by reducing non-complex carbohydrates and increasing vegetables, proteins, and complex carbohydrates. Within two weeks, her symptoms improved, including better sleep and energy levels, accompanied by a 3 kg weight loss following dietary adjustments informed by CGM feedback. Conclusions: This case suggests how CGM can empower patients having undergone bariatric surgery to manage glucose fluctuations through informed self-management. The patient’s ability to identify and address glucose variability without formal intervention highlights CGM’s potential as a supportive tool in long-term care. While further studies are needed, this case suggests CGM may benefit similar patients experiencing postprandial symptoms or weight regain after bariatric surgery. Full article

Dumping Syndrome (DS) is a significant complication following bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB). This condition is characterised by gastrointestinal and vasomotor symptoms resulting from altered anatomy and hormonal dysregulation, notably accelerated gastric emptying and an exaggerated release of gut peptides. Based on the timing of symptom onset after food ingestion, DS is classified as early (EDS) or late (LDS). The critical roles of peptides such as GLP-1, GIP, insulin, and YY peptide are highlighted, along with the involvement of neuroendocrine pathways in symptom manifestation. Diagnosis relies on a combination of clinical evaluation and dynamic testing, with the oral glucose tolerance test (OGTT) often considered a key reference standard for diagnosis. Initial management involves dietary modifications, emphasising the glycaemic index of foods and meal distribution. In cases where nutritional interventions are insufficient, pharmacotherapy with agents such as acarbose, somatostatin analogues (octreotide and pasireotide), GLP-1 receptor agonists (liraglutide), calcium channel blockers (verapamil), and emerging therapies, including herbal medicine, may be considered. For refractory cases, surgical options like bypass reversal or partial pancreatectomy are reserved, although their efficacy can be variable. Despite advancements in understanding and treating DS, further large-scale, randomised controlled trials are essential to validate novel strategies and optimise long-term management. This review provides an updated and comprehensive overview of the aetiology, pathophysiological mechanisms, diagnostic approaches, and current management strategies for DS. Full article

Background: Bariatric surgery (BS) is the most effective long-term treatment for severe obesity, but many patients develop food intolerances that either reduce protein and micronutrient intake or shift consumption toward easily tolerated, calorie-dense “safe” foods (e.g., sweets, ice cream, sugar-sweetened beverages, refined-flour snacks), compromising nutrient adequacy and weight-loss maintenance. This narrative review summarizes evidence on the prevalence, mechanisms, and clinical impact of food intolerances after BS, focusing on red meat, dairy, water, cereal, and vegetables, and offers practical nutritional management strategies. Methods: A targeted literature search of PubMed and Cochrane Library from the past 10 years was conducted. Studies were selected based on relevance and quality. Results: Intolerance patterns vary by food type and surgical method. Red meat is the most frequently problematic food, with some patients symptomatic for years despite gradual improvement. Dairy products cause gastrointestinal discomfort in some cases, partly due to lactose intolerance. Cereal products may initially cause swallowing difficulties but are generally well tolerated two years postoperatively. Water intolerance mainly occurs shortly after sleeve gastrectomy (SG), linked to sleeve aperistalsis and edema, resolving within weeks. Cooked vegetables are overall well tolerated across procedures. Mechanisms behind intolerance include mechanical restriction, altered gastric emptying, exaggerated entero-hormonal responses, and new taste aversions. Conclusions: Food intolerances are a common, procedure-specific consequence of BS, requiring systematic assessment and personalized dietary management. Early management—modification of consistency, portion control, and supplementation—can improve product tolerance, prevent nutritional deficiencies, and support sustainable weight loss. However, further prospective studies on the mechanisms of food intolerances are needed. Full article

The gastrointestinal (GI) tract is increasingly recognized as an important regulator of energy balance and metabolism, extending beyond its traditional digestive functions. This review synthesizes current research on how modifications to the GI tract, particularly those induced by metabolic bariatric surgery (MBS), influence hormonal and physiological processes involved in glucose regulation and appetite control. MBS procedures, such as Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), induce significant and sustained weight loss, but also elicit adaptive morphological and functional changes within the intestines. These alterations include intestinal hypertrophy, increased mucosal surface area, changes in nutrient transit time, and modifications in enzyme activity. Such changes enhance the secretion of key gut hormones, including glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), which play vital roles in promoting insulin secretion, suppressing appetite, and improving blood glucose regulation. The benefits stem from the exposure of undigested nutrients to different intestinal segments, which stimulates enteroendocrine activity and positively influences systemic metabolism. These hormonal adaptations contribute significantly to the metabolic improvements observed post-surgery, independent of weight loss alone. Understanding how gut structural and functional changes drive hormonal responses provides valuable insights into the mechanisms underlying the success of MBS. Moreover, elucidating these processes may facilitate the development of less invasive therapies that mimic the metabolic benefits of surgery. Ultimately, this research advances our understanding of gut-mediated regulation of energy and glucose homeostasis and holds promise for improving treatment strategies for obesity and related metabolic disorders. Full article

Background and Objectives: Iron deficiency anaemia (IDA) is a common consequence of bariatric and metabolic surgery (BMS). Women are at higher risk, and some patients cannot tolerate oral iron. This study aimed to report the demographics of patients with IDA that required iron infusion post-BMS and to investigate risk factors including gynaecological dysfunction. Materials and Methods: The medical records for all patients (n = 383) post-BMS at a large tertiary centre from January 2017 to December 2024 were reviewed, and those who received intravenous iron infusion (n = 32) for IDA were included. The criteria for iron infusion were ferritin < 50 µg/L or intolerance to oral iron. Demographic information including co-morbidities—gynaecological and other—age, pre-operative weight, body mass index (BMI), and ferritin levels were collected to investigate possible risk factors for IDA. Results: Thirty-two patients, all female, received one or more parenteral iron infusions. Eighteen had surgery locally; 14 had surgery elsewhere. Operations varied and included 14 Roux-en-Y gastric bypasses, 14 sleeve gastrectomy’s, and 4 gastric bands or other procedures. Eleven patients had a history of gynaecological disorders. Pre-infusion ferritin levels in the cohort with gynaecological disorders versus the cohort without were lower (median 11.0 vs. 14.5 µg/L), with a shorter time to presentation (median 6.9 vs. 10.2 years), and more patients requiring >2 infusions for resolution of symptoms (36.4% vs. 9.5%). Conclusions: Locally, 95% of our patients did not require iron infusion post-BMS. Eighty percent of those who did require iron infusion responded to ≤2 infusions. Women with a history of gynaecological disorder who underwent BMS required a significantly higher number of iron infusions and presented with symptoms sooner post-operatively vs. those without gynaecological disorders, particularly following Roux-en-Y gastric bypass. This is an important observation to consider both pre- and post-operatively for patients undergoing bariatric surgery, and additional well-designed studies that investigate this further are needed. Full article

Background/Objectives: Introduction: Bariatric surgery, including laparoscopic sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), is an effective treatment for severe obesity and its metabolic complications. This study aimed to assess and compare the clinical outcomes of both procedures over a 24-month follow-up. Few studies have compared 24-month SG and RYGB results in terms of metabolic and nutritional profiles in the Polish cohort. Materials and Methods: A retrospective analysis was conducted on 54 patients (27 SG, 27 RYGB) treated between 2018 and 2022. Anthropometric (body weight, BMI), biochemical (lipid profile, glucose, HbA1c, and liver enzymes), and nutritional (iron, ferritin, and vitamin B12) parameters were measured at 1, 6, 12, and 24 months postoperatively. Results: Both surgical techniques led to a significant reduction in body weight and BMI during the first postoperative year. After 24 months, weight stabilization was observed in the RYGB group, while statistically significant weight regain occurred in the SG group (p < 0.0001). HDL levels significantly increased and triglyceride levels decreased in both groups (p < 0.0001), with no significant changes in LDL levels. AST, ALT, decreased dramatically at the first measurement in both methods, while a greater decrease in glycemia was recorded with the SG method (at the same time). A significant reduction in ferritin and vitamin B12 levels was observed in both groups but was more pronounced after RYGB. Iron levels increased until 12 months, followed by a decline by month 24. Conclusions: Both RYGB and SG are effective for weight loss and metabolic improvement. RYGB demonstrates greater long-term weight stability but carries a higher risk of nutritional deficiencies. SG should be the first method to consider due to its lower risk, invasiveness, and lower risk of nutritional deficiencies. Full article

Background/Objectives: GaBHA syndrome (gastric bypass hyperammonemia) is an emerging new syndrome primarily in women who had prior Roux-en-Y gastric bypass surgery (RYGB) and then developed non-cirrhotic hyperammonemia with a high case–fatality ratio. Genetic and nutritional deficiencies have been implicated in the pathogenesis of this clinical condition, but none has been proven. We present an illustrative case and do a scoping review of the current literature in 58 patients with this diagnosis. Methods: A retrospective scoping literature review was utilized to identify patients who fulfilled 1. RYGB surgery, and 2. Hyperammonemic encephalopathy following the PRISMA extended checklist. We searched PubMed, MedLine, SCOPUS, and Web of Science databases. Results: We described the classic presenting symptoms and laboratory findings of this syndrome. We confirmed the female predominance (93%) and the high case–fatality ratio (32%). We then presented a novel hypothesis contending that arginine deficiency ultimately leads to a functional deficiency of the ornithine transcarbamolyase (OTC) enzyme, leading to the non-cirrhotic life-threatening hyperammonemia. Our hypothesis may also explain the high incidence of hypoglycemia found in these patients as we found in our search. Our proposed hypothesis may also be relevant to the occurrence of hyperammonemia in some solid organ transplant recipients. Conclusions: GaBHA syndrome is emerging as an important potential adverse outcome after RYGB surgery. It has a female predominance and a high case–fatality ratio. Arginine deficiency may explain the emergence of a functional OTC deficiency, which then leads to the severe hyperammonemia, and may also explain the frequent occurrence of hypo-glycemia in these patients. Full article

Bariatric surgery is considered the most effective treatment for obesity and its associated metabolic disorders, yet the underlying mechanisms are only partially understood. Evidence suggests that the gut microbiota plays an important role in metabolic regulation and can be significantly altered by bariatric and metabolic procedures. This prospective, single-center study aimed to evaluate the dynamic changes in the gut microbiota composition and diversity in obese patients undergoing two types of bariatric surgery: laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB). Fecal samples were collected at three time points—before surgery (T0), and at 3 (T3) and 6 months (T6) postoperatively—and analyzed using 16S rRNA gene sequencing targeting the V3–V4 regions with Illumina technology. Significant shifts in microbial diversity and structure were observed over time, indicating a trend toward microbiota normalization post-surgery. Notable changes included a reduction in the Firmicutes/Bacteroidetes ratio and increased relative abundance of Actinobacteria, Proteobacteria, and Verrucomicrobia. These alterations occurred in parallel with improvements in body mass index (BMI) and metabolic parameters. Our findings suggest that bariatric surgery induces favorable and sustained modifications in the gut microbiota, which may contribute to its therapeutic effects in obesity management. Full article

Background and Objectives: Ghrelin plays key roles in appetite regulation, involving both homeostatic and hedonic pathways. In obesity, its metabolism is affected by alterations in neural and hormonal responses. Liver-Enriched Antimicrobial Peptide 2 (LEAP2), recently identified as an endogenous ghrelin receptor antagonist, has emerged as a potential regulator of appetite and energy balance, and bariatric surgery is known to induce changes in this system. In this review, we aimed to evaluate the roles of acyl ghrelin, des-acyl ghrelin, and LEAP2 in food intake regulation and summarize findings on the alterations in their levels after bariatric surgery. Materials and Methods: We conducted a narrative review of human and animal studies published in the literature investigating the roles of acyl ghrelin, des-acyl ghrelin, and LEAP2 in food intake regulation, as well as changes in their levels in obesity and following bariatric surgery. Results: Alterations in the ghrelin system, i.e., the acyl ghrelin and des-acyl ghrelin isoforms and LEAP2, in obesity have been reported. Experimental studies have shown that LEAP2 administration reduces food intake and body weight by suppressing ghrelin-induced food intake. Most studies have found marked reductions in fasting acyl ghrelin after sleeve gastrectomy, more so than after Roux-en-Y gastric bypass. Conclusions: In obesity, altered neural and hormonal responses to food also affect ghrelin metabolism, with significant deviations in acyl ghrelin levels and impaired appetite regulation mechanisms. Unlike ghrelin, LEAP2 levels tend to be elevated in obesity. While changes in acyl ghrelin and des-acyl ghrelin isoforms, particularly after sleeve gastrectomy, are well documented, data on LEAP2 remain limited. Further research is needed to better define the role of LEAP2 in ghrelin-mediated food intake and its potential as a therapeutic target in obesity. Full article

Patients with Roux-en-Y gastric bypass (RYGB) are a significant challenge for endoscopic retrograde cholangiopancreatography (ERCP) due to the altered anatomy. Endoscopic ultrasound (EUS)-directed transgastric ERCP (EDGE) has emerged as a valuable alternative to standard methods like enteroscopy-assisted (EA-ERCP) and laparoscopy-assisted (LA-ERCP) ERCP. EDGE involves creating a temporary fistula between the gastric pouch and the excluded stomach under EUS guidance, typically using a lumen-apposing metal stent (LAMS). This allows a standard ERCP scope to access the second duodenum and the biliary tree with standard devices. Several studies have investigated the efficacy and safety of this approach, with variations in techniques such as suturing the LAMS to prevent migration. EDGE has demonstrated high technical success rates, and current evidence indicates that it can be performed safely, with acceptable rates of adverse events such as stent migration, bleeding, and perforation, making it the preferred option in referral centers. This comprehensive review aims to provide a concise evaluation of EDGE, its techniques, outcomes, and role in managing biliary and pancreatic disorders in RYGB patients. Full article

Background/Objectives: Gastroesophageal reflux disease (GERD) seems to be a common complaint which persists or develops after metabolic bariatric surgery (MBS). Endoscopic evaluation is vital in both the preoperative and postoperative phases to ensure optimal patient outcomes. The aim of this study was to evaluate the prevalence of GERD after MBS in a 10-year follow-up and analyze the endoscopic outcomes. Methods: This retrospective, multicenter study included 368 patients who underwent single bariatric procedure. The data came from five bariatric centers in Poland, part of the BARI-10-POL project. Data on symptoms of GERD, endoscopic findings, demographics, and surgical outcomes were collected for a 10-year follow-up period. Surgical procedures included SG, Roux-en-Y gastric bypass (RYGB), and one anastomosis gastric bypass (OAGB). Results: Of the 305 patients without symptoms of GERD, 12.3% developed de novo GERD postoperatively. There was no statistical significance regarding the new-onset symptoms and the type of MBS (p = 0.074) and the presence of symptoms of GERD and the type of MBS (p = 0.208). However, SG was associated with a significantly lower likelihood of GERD remission after MBS (p = 0.005). Endoscopic evaluation showed abnormal findings in asymptomatic patients in both preoperative (35.8%) and postoperative (14.1%) examinations (p < 0.001). Conclusions: GERD may be a common issue after MBS. One-quarter of patients after MBS may experience symptoms of GERD, regardless of the type of MBS. SG appears to be associated with a higher risk of persistent symptoms of GERD and a lower likelihood of GERD remission after MBS. Asymptomatic patients both before and after MBS may have abnormal findings in gastroscopy. Full article

Background: Despite being one of the most performed bariatric procedures, there is no consensus regarding optimal limb lengths for Roux-en-Y gastric bypass (RYGB), which may impact weight loss and obesity-related comorbidity resolution. We hypothesize that a ratio-adjusted small bowel to Roux and BP limb lengths in RYGB results in superior outcomes. Objectives: This study aims to define total intestinal length (TIL) and the feasibility of its intraoperative measurement during RYGB. The findings will serve as a foundation for a subsequent randomized trial evaluating different limb length ratios and their effect on postoperative outcomes. Setting: This was a single-center prospective cohort study conducted at Cleveland Clinic Foundation-Main Campus, a tertiary referral center in the United States. Methods: Between January and June 2023, 25 patients with BMI > 40 undergoing RYGB were enrolled. Total small bowel length was measured intraoperatively, and feasibility of measurement was assessed. Patient outcomes, including total weight loss, 30-day complications, and comorbidities at 1 year were captured. Results: Mean preoperative BMI was 47.6 ± 8.0 kg/m². Mean total small bowel length was 592 ± 93.3 cm, with a mean biliopancreatic (BP) limb length of 109 ± 29 cm (18.86% ± 5.84 of total length) and Roux limb length of 103 ± 15 cm (17.71% ± 3.06 of total length). Measurement added an average of 11.5 min to operative time. Measurement feasibility was rated as “moderate” or easier in 80% of cases. One-year postoperative outcomes included a mean total weight loss of 31% and significant reductions in antihypertensive and anti-diabetic medication use. Conclusions: Total small bowel length measurement during RYGB is safe and feasible. High variability in bowel length was observed, with no significant correlation to demographic factors. Establishing individualized limb length ratios may improve weight loss outcomes and comorbidity resolution. Further studies are warranted to evaluate the impact of tailored limb length strategies. Full article

Roux-en-Y gastric bypass (RYGB) surgery induces profound gut microbiota alterations that may impact metabolic outcomes. This study investigated site-specific effects of a multicomponent bovine colostrum-honey-serviceberry (CHJ) complex on post-RYGB microbiome changes in obese rats. Twenty-nine Wistar rats underwent RYGB surgery with CHJ supplementation, followed by mucosal-associated microbiota analysis from five gastrointestinal segments using 16S rRNA sequencing and serum metabolite profiling. RYGB caused regional-specific changes: decreased alpha diversity, systematic Proteobacteria increases (31.2 ± 5.1% in duodenum), and reductions in SCFA-producing bacteria (Romboutsia, Roseburia). CHJ supplementation exhibited dual effects on the microbiome: restoration of beneficial bacteria (Lactobacillus, Bifidobacterium) in distal segments while concurrently promoting Enterobacteriaceae growth in proximal regions. CHJ also maintained alpha diversity levels of the mucosa-associated microbiota comparable to those observed in the control group. Disconnects emerged between predicted microbial functions and systemic metabolites: thiamine pathway activation accompanied 78.5% serum vitamin B1 reduction, indicating severe absorption deficits. Three distinct patterns emerged: pro-inflammatory (proximal), decolonization (widespread Helicobacteraceae loss), and restorative (selective CHJ-mediated recovery). Results demonstrate that post-RYGB dysbiosis exhibits profound regional heterogeneity requiring segment-specific interventions and highlight complex interactions between nutritional supplementation and surgically altered gut ecology in determining metabolic outcomes. Full article

Background: Bariatric surgeries, specifically laparoscopic sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), are a common intervention for morbid obesity, significantly affecting food tolerance and quality of eating. Understanding these changes is crucial for improving postoperative care and long-term success. Methods: This observational study at University Hospital Mannheim involved 91 patients, aged between 18 and 65 year, who underwent SG or RYGB between 2009 and 2019. Food tolerance was assessed between 25 days and 117 months after surgery using the validated score by Suter et al. (Food Tolerance Score, FTS) and an additional score evaluating tolerance to specific food groups and quality of life. Data on body composition were collected through Bioelectrical Impedance Analysis (BIA) at follow-up visits. Statistical analyses included linear mixed models to analyze the association of food tolerance with body composition changes. Results: The FTS indicated moderate or poor food tolerance in 62.6% of patients, with no significant differences between SG and RYGB. Considering the results of the additional score, food groups such as red meat, wheat products, raw vegetables, carbon dioxide, fatty foods, convenience food, and sweets were the most poorly tolerated food groups. A total of 57 of the participants had a baseline and follow-up BIA measurement. Postoperatively, a significant reduction in body weight and BMI as well as in BIA parameters (fat mass, lean mass, body cell mass, and phase angle) was found. Quality of life improved after bariatric surgery and 76.9% rated their nutritional status as good or excellent, despite possible food intolerances. Conclusions: Bariatric surgery significantly reduces weight and alters food tolerance. Despite moderate or poor food tolerance, patients reported high satisfaction with their nutritional status and quality of life. Detailed food tolerance assessments and personalized dietary follow-ups are essential for the early detection and management of postoperative malnutrition, ensuring sustained weight loss and improved health outcomes. Full article